Holen Sie sich die Stockscreener-App
50.90
2.25%
1.12
Handel nachbörslich:
51.15
0.25
+0.49%
Überblick
Nachrichten
Preisverlauf
Optionskette
Warum fällt NVO?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$49.78
Offen:
$50.28
24-Stunden-Volumen:
19.38M
Relative Volume:
1.37
Marktkapitalisierung:
$172.56B
Einnahmen:
$45.44B
Nettoeinkommen (Verlust:
$16.18B
KGV:
14.01
EPS:
3.634
Netto-Cashflow:
$9.21B
1W Leistung:
+12.16%
1M Leistung:
-26.16%
6M Leistung:
-35.43%
1J Leistung:
-61.89%
1-Tages-Spanne:
$50.24
$51.23
1-Wochen-Bereich:
$47.92
$51.30
52-Wochen-Spanne:
$45.05
$139.74
Novo Nordisk Adr Stock (NVO) Company Profile
Vergleichen Sie NVO mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
NVO
Novo Nordisk Adr
|
50.90 | 221.19B | 45.44B | 16.18B | 9.21B | 3.634 |
|
LLY
Lilly Eli Co
|
660.49 | 573.22B | 53.26B | 13.80B | -50.20M | 15.30 |
|
JNJ
Johnson Johnson
|
174.42 | 416.11B | 90.62B | 22.66B | 16.40B | 9.35 |
|
ABBV
Abbvie Inc
|
201.47 | 350.91B | 58.33B | 3.73B | 18.24B | 2.10 |
|
NVS
Novartis Ag Adr
|
121.20 | 230.97B | 53.40B | 13.68B | 16.81B | 6.9231 |
|
MRK
Merck Co Inc
|
82.71 | 200.57B | 63.43B | 16.42B | 14.72B | 6.49 |
Novo Nordisk Adr Stock (NVO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-08-05 | Herabstufung | UBS | Buy → Neutral |
| 2025-07-31 | Herabstufung | HSBC Securities | Buy → Hold |
| 2025-07-30 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2025-04-17 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2025-03-13 | Hochstufung | Kepler | Hold → Buy |
| 2025-03-03 | Herabstufung | Stifel | Buy → Hold |
| 2025-02-12 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2025-01-06 | Hochstufung | Bernstein | Underperform → Mkt Perform |
| 2024-05-30 | Eingeleitet | Goldman | Buy |
| 2024-04-12 | Eingeleitet | BMO Capital Markets | Outperform |
| 2024-01-23 | Eingeleitet | Morgan Stanley | Overweight |
| 2024-01-16 | Fortgesetzt | UBS | Neutral |
| 2023-12-01 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-10-02 | Eingeleitet | Argus | Buy |
| 2023-07-14 | Eingeleitet | HSBC Securities | Buy |
| 2022-07-15 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2022-06-28 | Herabstufung | UBS | Neutral → Sell |
| 2022-06-27 | Hochstufung | Exane BNP Paribas | Underperform → Neutral |
| 2022-06-07 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2022-05-31 | Hochstufung | Guggenheim | Neutral → Buy |
| 2022-04-25 | Hochstufung | Cowen | Market Perform → Outperform |
| 2022-04-12 | Hochstufung | Morgan Stanley | Underweight → Equal-Weight |
| 2022-03-16 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2022-01-25 | Herabstufung | Liberum | Hold → Sell |
| 2021-12-20 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2021-12-17 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2021-01-20 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2021-01-15 | Eingeleitet | Deutsche Bank | Buy |
| 2020-09-29 | Eingeleitet | Berenberg | Hold |
| 2020-07-06 | Herabstufung | BofA Securities | Buy → Neutral |
| 2020-05-11 | Herabstufung | UBS | Buy → Neutral |
| 2020-05-04 | Eingeleitet | Cowen | Market Perform |
| 2020-03-16 | Hochstufung | BofA/Merrill | Neutral → Buy |
| 2020-01-03 | Herabstufung | Guggenheim | Buy → Neutral |
| 2019-11-18 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2019-09-17 | Hochstufung | Citigroup | Neutral → Buy |
| 2019-08-30 | Herabstufung | Jefferies | Hold → Underperform |
| 2019-06-20 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2019-06-11 | Hochstufung | Barclays | Underweight → Equal Weight |
| 2019-04-29 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2019-01-29 | Eingeleitet | Exane BNP Paribas | Outperform |
| 2018-12-11 | Fortgesetzt | Jefferies | Hold |
| 2018-10-09 | Eingeleitet | Guggenheim | Buy |
| 2017-12-29 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2017-12-06 | Hochstufung | BofA/Merrill | Neutral → Buy |
| 2017-12-01 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2017-09-25 | Herabstufung | Exane BNP Paribas | Outperform → Neutral |
| 2017-09-06 | Hochstufung | BofA/Merrill | Underperform → Neutral |
Alle ansehen
Novo Nordisk Adr Aktie (NVO) Neueste Nachrichten
Why Novo Nordisk Stock Topped the Market Today - The Motley Fool
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Novo Nordisk A/S of Class Action Lawsuit and Upcoming Deadlines – NVO - FinancialContent
HIMS & HERS HEALTH SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuits Against Hims & Hers Health, Inc. - GlobeNewswire Inc.
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Novo Nordisk A/S of Class Action Lawsuit and Upcoming Deadlines - GlobeNewswire Inc.
Real time scanner hits for Novo Nordisk A s (b Shares) Adrhedged explainedBuy/Sell Zone Confirmation Technical Analysis - Newser
Novo Nordisk A/S Common Stock (NYSE:NVO) Stock Quote - FinancialContent
Will a bounce in Novo Nordisk A s (b Shares) Adrhedged offer an exitNext Day Momentum Stock Forecasting Report - Newser
European ADRs Tick Up As Healthcare And Industrials Shine - Finimize
Applying sector rotation models to Novo Nordisk A s (b Shares) AdrhedgedPredictive AI Signals for Short-Term Trading - Newser
Why Novo Nordisk A s (b Shares) Adrhedged stock attracts strong analyst attentionIntraday Strategy with Real Time Monitoring - Newser
Does Novo Nordisk A s (b Shares) Adrhedged qualify in momentum factor screeningFree Market Surge Signal for Swing Traders - Newser
Published on: 2025-08-06 19:02:41 - Newser
Novo Nordisk Earnings: CVS Deal, Oral Semaglutide Support Growth Despite Compounding Uncertainty - Morningstar
Is Novo Nordisk A s (b Shares) Adrhedged trending in predictive chart modelsFree AI Screening for Swing Trade Picks - Newser
Novo Nordisk lowers 2025 sales outlook, ADR price falls 21.83%. - AInvest
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Novo Nordisk A/SNVO - cnhinews.com
Novo Nordisk ADR earnings beat by $0.04, revenue fell short of estimates - Investing.com
Novo Nordisk A/S Announces 7% Increase in Interim Dividend for 2025, Payment Dates Set - AInvest
Novo Nordisk ADR earnings beat by $11.56, revenue topped estimates - Investing.com India
How to monitor Novo Nordisk A s (b Shares) Adrhedged with trend dashboardsFree Alpha Focused Technical Trade Signals - Newser
Chart based exit strategy for Novo Nordisk A s (b Shares) AdrhedgedVolume Confirmed Setup with Entry Confidence - Newser
Novo Nordisk A s (b Shares) Adrhedged’s volatility index tracking explainedMomentum Prediction Based on AI Backtesting - Newser
Novo faces shareholder lawsuit over guidance cut - MSN
Novo Nordisk ADR’s Bumpy Road: Analyzing the 52-Week Range and Future Prospects - investchronicle.com
Is Novo Nordisk A s (b Shares) Adrhedged forming a bottoming baseHistorical Stock Summary and ROI Review - Newser
Will earnings trigger a reversal in Novo Nordisk A s (b Shares) AdrhedgedMarket Correction Proof Stock Screening Analysis - Newser
What makes Novo Nordisk A s (b Shares) Adrhedged stock price move sharplyOver 200% growth - Jammu Links News
How many analysts rate Novo Nordisk A s (b Shares) Adrhedged as a “Buy”Superior investment outcomes - Jammu Links News
Published on: 2025-08-03 21:00:40 - Jammu Links News
INVESTOR DEADLINE: Robbins Geller Rudman & Dowd LLP Announces that Hims & Hers Health, Inc. Investors with Substantial Losses Have Opportunity to Lead Securities Class Action Lawsuit - GlobeNewswire Inc.
How volatile is Novo Nordisk A s (b Shares) Adrhedged stock compared to the marketSkyrocketing returns - Jammu Links News
How strong is Novo Nordisk A s (b Shares) Adrhedged company’s balance sheetOutstanding trading profits - Jammu Links News
Should I hold or sell Novo Nordisk A s (b Shares) Adrhedged stock in 2025Unlock real-time trading signals for gains - Jammu Links News
Is Novo Nordisk A s (b Shares) Adrhedged a growth stock or a value stockAchieve explosive financial results today - Jammu Links News
Finanzdaten der Novo Nordisk Adr-Aktie (NVO)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.53%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):